Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIA-002 safety trial of PRO 2000/5 vaginal gel versus placebo in Uganda
ISRCTN02518250Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jun 2003
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, randomised trial of PRO 2000 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Imperial College London. Primary endpoints: Genital epithelial disruption and Clinically relevant coagulation abnormality. Started Jun 2003; status: completed.
02
Drugs
PRO 2000
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN02518250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN02518250.